Supplements

Saw palmetto: berry extracts, placebo-controlled urinary results, escalating exposure, European medicinal categories, PSA, and safety limits

7 sources · Latest source check 2026-10-09 UTC

On this page

Saw palmetto is a Serenoa repens fruit preparation. Dependable placebo-controlled evidence generally shows little or no benefit for urinary symptoms attributed to benign prostate enlargement. European medicinal assessments distinguish particular extracts. Their categories do not establish that every supplement works.[1]

The names identify a plant, a preparation and an outcome

The names identify a plant, a preparation and an outcome
Term	Meaning
Saw palmetto	Serenoa repens fruit preparations.[1]
BPH	Noncancerous prostate enlargement.[6]
AUASI	The American Urological Association Symptom Index.[3]
Hexane versus ethanol extract	Different preparations assessed under different EMA categories.[6]

Symptoms and objective measurements did not significantly improve

The symptom-score difference was 0.04 points, with a 95% interval from −0.93 to +1.01. Urinary flow, prostate size, residual urine and quality-of-life comparisons also lacked significant effects. A proposed hormonal or anti-inflammatory mechanism therefore did not translate into demonstrated benefit in this trial.[3]

CAMUS tested progressively higher exposure

Barry and colleagues’ 2011 CAMUS report compared escalating saw-palmetto extract exposure with placebo over 72 weeks. Its main comparison was change in urinary symptom score from baseline. Increasing exposure was a tested hypothesis, rather than proof that a higher amount would overcome an earlier negative result.[4]

Both groups improved, without an advantage for the extract

Scores fell about 2.20 points with extract and 2.99 with placebo. The between-group difference favored placebo by 0.79 points; saw palmetto did not show superiority. Measuring improvement within the extract group alone would omit the control group’s improvement. Dose-response analysis likewise did not demonstrate greater improvement with extract.[4]

Secondary measures did not provide a demonstrated rescue effect

The report did not establish superiority for its secondary outcomes either. These included urinary bother, nighttime urination, flow, residual urine, PSA and other symptom measures. The selected indexed original methods/results were inspected. Complete endpoint multiplicity, missing-data and sponsor-role appraisal remains pending. Its published correction is explained below.[4]

A published correction changed several reported details

JAMA’s 2012 correction revised the extract-group change interval to −3.04 to −1.36, and corrected responder percentages to 48.9% with extract and 52.5% with placebo. The corrected repeated-measures comparison was also nonsignificant. These details supersede older indexed versions; they do not establish extract superiority.[5]

EMA distinguishes well-established and traditional medicinal use

EMA’s public explanation identifies well-established medicinal use for specified hexane-extracted fruit preparations and traditional medicinal use for ethanol extracts in BPH-associated lower urinary tract symptoms. Traditional use includes plausible effectiveness and a history of use despite insufficient clinical-trial evidence. It should not be read as the same evidential judgment as proven placebo superiority.[6]

The medicinal assessment and the review use different comparisons

EMA describes older clinical comparisons with established BPH medicines when explaining its hexane assessment. The placebo-controlled research summarized here asks whether symptoms improve more than with placebo. Preparation differences, comparator choice, assessment dates and study eligibility all require reconciliation before treating the sources as equivalent or declaring that one automatically overrides another.[6]

An assessment category is specific to its preparation and indication

The agency’s public summary concerns adult and older men, particular fruit extracts and BPH-associated symptoms after serious conditions are excluded. National authorities license medicines. The selected original indexed summary was inspected; complete national labeling, updated assessment and active-comparator equivalence appraisal remain pending.[6]

The CAMUS safety publication shares the same experiment

Avins and colleagues’ 2013 safety report describes 369 randomized participants, with 357 in its modified intention-to-treat analysis. The studied ethanolic extract increased in exposure at six-month intervals across eighteen months. This companion paper adds safety detail; it is not another independent efficacy trial.[7]

No detected toxicity difference does not certify every product

The report found no significant between-group differences in serious or nonserious adverse events, vital signs or withdrawal rates, and no meaningful overall laboratory-toxicity signal. Its conclusion concerned the tested extract and follow-up period. Rare events, other preparations, different populations and longer exposure remain separate questions.[7]

The analysis denominator matters for interpreting reassurance

The modified analysis included fewer people than were randomized. Complete missing-data, event ascertainment and sponsor-role appraisal remains pending. A nonsignificant harm comparison cannot rule out every possible adverse effect, and tolerability does not supply efficacy when symptom comparisons are negative.[7]

Other claims and populations have less dependable evidence

NCCIH describes usually mild digestive symptoms, dizziness or headache, uncertain evidence for other proposed uses and pregnancy or breastfeeding concerns. Hair-growth marketing requires its own outcome evidence. A fruit-derived supplement does not establish an individual urinary-treatment or hormonal regimen.[1]

Evidence & uncertainty

The 2023 Cochrane review found little or no symptom benefit. Its search ended September 2022; this is a dated synthesis, not independent Atlas grading.[2]

Selected-source overview · Independent review pending

Published questions

Did the one-year Bent trial establish significant urinary symptom or flow benefit?

Selected-source overview · Independent review pending. Read the evidence context.

It did not.[3]

Evidence behind this answer

Saw palmetto for benign prostatic hyperplasia
randomized trial · 2006
Original full abstract inspected; complete trial-level appraisal pending · 2006 full abstract: 225 men, one year, symptom/flow and PSA comparisons